We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DaVita HealthCare (DVA) Stock Moves -1.01%: What You Should Know
Read MoreHide Full Article
In the latest trading session, DaVita HealthCare (DVA - Free Report) closed at $187.25, marking a -1.01% move from the previous day. The stock's performance was ahead of the S&P 500's daily loss of 1.09%. Elsewhere, the Dow lost 0.34%, while the tech-heavy Nasdaq lost 2.15%.
Prior to today's trading, shares of the kidney dialysis provider had gained 3.32% outpaced the Medical sector's gain of 2.68% and the S&P 500's gain of 2.44%.
The investment community will be paying close attention to the earnings performance of DaVita HealthCare in its upcoming release. The company is forecasted to report an EPS of $3.78, showcasing a 50.6% upward movement from the corresponding quarter of the prior year. Alongside, our most recent consensus estimate is anticipating revenue of $3.53 billion, indicating a 3.23% upward movement from the same quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $14.57 per share and a revenue of $14.28 billion, representing changes of +35.16% and +4.67%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for DaVita HealthCare. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. At present, DaVita HealthCare boasts a Zacks Rank of #3 (Hold).
In terms of valuation, DaVita HealthCare is presently being traded at a Forward P/E ratio of 12.98. This represents a discount compared to its industry average Forward P/E of 20.96.
Investors should also note that DVA has a PEG ratio of 0.49 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Outpatient and Home Healthcare stocks are, on average, holding a PEG ratio of 1.82 based on yesterday's closing prices.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. With its current Zacks Industry Rank of 72, this industry ranks in the top 30% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
DaVita HealthCare (DVA) Stock Moves -1.01%: What You Should Know
In the latest trading session, DaVita HealthCare (DVA - Free Report) closed at $187.25, marking a -1.01% move from the previous day. The stock's performance was ahead of the S&P 500's daily loss of 1.09%. Elsewhere, the Dow lost 0.34%, while the tech-heavy Nasdaq lost 2.15%.
Prior to today's trading, shares of the kidney dialysis provider had gained 3.32% outpaced the Medical sector's gain of 2.68% and the S&P 500's gain of 2.44%.
The investment community will be paying close attention to the earnings performance of DaVita HealthCare in its upcoming release. The company is forecasted to report an EPS of $3.78, showcasing a 50.6% upward movement from the corresponding quarter of the prior year. Alongside, our most recent consensus estimate is anticipating revenue of $3.53 billion, indicating a 3.23% upward movement from the same quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $14.57 per share and a revenue of $14.28 billion, representing changes of +35.16% and +4.67%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for DaVita HealthCare. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. At present, DaVita HealthCare boasts a Zacks Rank of #3 (Hold).
In terms of valuation, DaVita HealthCare is presently being traded at a Forward P/E ratio of 12.98. This represents a discount compared to its industry average Forward P/E of 20.96.
Investors should also note that DVA has a PEG ratio of 0.49 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Outpatient and Home Healthcare stocks are, on average, holding a PEG ratio of 1.82 based on yesterday's closing prices.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. With its current Zacks Industry Rank of 72, this industry ranks in the top 30% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.